Vadastuximab talirine

Last updated
Vadastuximab talirine
Vadastuximab talirine.svg
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD33
Clinical data
Other namesSGN-CD33A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII

Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). [1] [2]

Contents

Development of vadastuximab talirine was discontinued in 2017 after a pivotal phase III clinical trial. [3]

Target, mAb, linker, and cytotoxin

The drug target, CD33, is expressed on most AML cells. The CD33 antibody is attached to a highly potent DNA binding agent, a pyrrolobenzodiazepine (PBD) dimer (SGD-1882), via a proprietary site-specific conjugation chemistry via a cleavable (valine-alanine dipeptide as cathepsin B cleavage site) maleimidocaproyl type linker, to a monoclonal antibody with engineered cysteines (EC-mAb). Vadastuximab talirine contains two site-specific drug attachment engineered cysteines. This use of engineered cysteine residues at the sites of drug linker attachment results in a drug loading of approximately 2 PBD dimers per antibody. PBD dimers are significantly more potent than systemic chemotherapeutic drugs and the site-specific conjugation technology (EC-mAb) allows uniform drug-loading of the cell-killing PBD agent to the anti-CD33 antibody. [4]

Clinical trials

The drug has concluded phase I clinical trials for acute myeloid leukemia. [5] Interim results were presented in Dec 2014. [6] and published April 2015. [7]

Based on interim data from ongoing phase I clinical trials presented at the 57th Annual Meeting of the American Society of Hematology (ASH), researchers at Seattle Genetics have planned a phase III clinical trial to begin in 2016. This phase III study is expected to evaluate vadastuximab talirine in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in previously untreated older AML patients. The drug is also being evaluated broadly across multiple lines of therapy in patients with myeloid malignancies, including in ongoing and planned phase I and II clinical trials for newly diagnosed or relapsed AML and for newly diagnosed myelodysplastic syndrome or MDS. [4]

A phase III clinical trial of Vadastuximab talirine in combination with hypomethylating agents, was terminated, however, in June 2017 due to a higher rate of deaths resulting from fatal infections. [3] [8]

Orphan drug designation

Vadastuximab talirine was granted orphan drug designation by both the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of AML. [4]

References

  1. ↑ Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Harrington KH, et al. (November 2012). "SGN-CD33A: A novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML". Blood. 120 (21): 3589. doi:10.1182/blood.V120.21.3589.3589.
  2. ↑ "Pyrrolobenzodiazepine (PBD)". ADC Review / Journal of Antibody-drug Conjugates. 16 March 2015.
  3. 1 2 Hartley JA (July 2021). "Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy". Expert Opinion on Biological Therapy. 21 (7): 931–943. doi:10.1080/14712598.2020.1776255. PMID   32543981. S2CID   219725417.
  4. 1 2 3 "Vadastuximab talirine (SGN-CD33a) drug description". ADC Review / Journal of Antibody-drug Conjugates. 23 November 2015.
  5. ↑ Clinical trial number NCT01902329 for "A Safety Study of SGN-CD33A in AML Patients" at ClinicalTrials.gov
  6. ↑ Stein EM, Stein A, Walter RB, Fathi AT, Lancet JE, Kovacsovics TJ, et al. (November 2014). "Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML)". Blood. 124 (21): 623. doi:10.1182/blood.V124.21.623.623.
  7. ↑ Kennedy DA, Alley SC, Zhao B, Feldman EJ, O'Meara M, Sutherland M (April 2015). Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Proceedings: AACR 106th Annual Meeting 2015. Philadelphia, PA. doi:10.1158/1538-7445.AM2015-DDT02-04. Abstract DDT02-04: SGN-CD33A: Preclinical and phase I interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
  8. ↑ Clinical trial number NCT02785900 for "Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.